Antibiotic resistance is tightening its grip on global healthcare, but the pipeline of truly new treatments remains thin.
That imbalance — rising need, limited innovation — has become a defining theme in infectious disease biotech. And it’s one that Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) Ltd is aiming to tackle with a new class of synthetic anti-infectives now advancing through late-stage trials.
Project generators are a familiar model in the junior resource sector, where companies acquire prospective ground, advance early-stage exploration, and bring in partners to fund further work. Purepoint Uranium Group Inc (TSX-V:PTU, OTCQX:PTUUF, FRA:P5X0) has followed a similar path, but with a more deliberate focus on retaining and advancing its core assets through long-term joint venture partnerships.
Entering Canada’s Athabasca Basin in the early 2000s, when uranium had been largely ignored by investors, Purepoint quietly assembled a portfolio of strategic claims. “At that time, nobody was looking for uranium,” CEO Chris Frostad told Proactive.
New Era Energy & Digital (NASDAQ:NUAI) announced that it has signed a non-binding letter of intent to form a joint venture aimed at developing and financing its Texas Critical Data Centers (TCDC) campus in West Texas.
The proposed partnership would bring together New Era, data center developer Stream Data Centers, and an unnamed institutional investor that would provide equity capital and help arrange project financing.
Tiziana Life Sciences Ltd (NASDAQ:TLSA) unveiled new preclinical data suggesting that its investigational therapy, intranasal foralumab, may offer a novel approach to addressing neuroinflammation associated with aging.
The company highlighted that neuro inflammation is widely recognized as a contributing factor to cognitive decline in age-related neurological conditions.
Graphene Manufacturing Group Ltd (TSX-V:GMG, OTCQX:GMGMF) announced that it has been certified as a Verified Graphene Producer by the Advanced Carbons Council.
The certification is part of the council’s Verified Graphene Producer program, which involves third-party validation of both the graphene material and its production process.
Bit Digital Inc (NASDAQ:BTBT) advanced its strategic shift toward Ethereum-focused treasury operations and artificial intelligence infrastructure in 2025, posting revenue growth and expanding its digital asset holdings.
According to its latest financials for the year ended December 2025, the company said total revenue for 2025 reached $113.6 million, representing a 5% increase from $108 million in 2024.
Digi Power X Inc (NASDAQ:DGXX, FRA:1NQ0, NEO:DGX) reported a year of significant balance sheet growth and a strategic pivot from cryptocurrency mining toward artificial intelligence (AI) infrastructure for the fiscal year ended December 31, 2025.
The company said cash and cash equivalents rose to $78.5 million from $1.7 million in the prior year. Total assets increased to $134.1 million, compared with $34.3 million in 2024, while shareholders’ equity grew to $123.3 million from $22.3 million. The company reported no outstanding debt at year-end.
Shares in Metals One PLC (AIM:MET1, FRA:HT7, OTCQB:MTOPF) rose 7% to 1.87p after the company announced a £1.5 million fundraise and an option to lift its stake in South African gold vehicle Lions Bay Resources to 49.9%, as it presses ahead with its strategy to build a vertically integrated gold business in the country.
The option allows Metals One to convert $5 million of its existing C$10 million secured loan facility into an additional 19.9% of Lions Bay Resources (LBR), taking its holding from 30% to just under 50%.
SP Angel initiates with a buy as a shallow exploration target hints at open-pit potential at Mushima North.
The publication of a JORC exploration target at Tertiary Minerals PLC (AIM:TYM, OTC:TTIRF, FRA:TMU) Mushima North project marks the first concrete step in what could become one of the more compelling small-cap silver stories on AIM.
Medicus Pharma (NASDAQ:MDCX) said on Wednesday its Phase 2 study of SkinJect (SKNJCT-003), a doxorubicin-containing microneedle array for nodular basal cell carcinoma (BCC), showed clinically meaningful activity, supporting plans to advance the therapy toward registrational development.
“We believe the positive topline results from 200 ug cohort at day 57, support the therapeutic value of SkinJect and establishes the best path forward towards registrational study,” said Dr. Raza Bokhari, executive chairman and CEO of Medicus.
Alvopetro Energy Ltd (TSX-V:ALV, OTC:ALVOF, FRA:A6Y0) said on Wednesday it has secured additional firm natural gas sales for 2026 and 2027 under an amended long-term agreement with Bahiagás, increasing contracted volumes and supporting higher expected production.
The Calgary-based company said the revised deal raises firm gas sales by 25% to 500 thousand cubic metres per day, with an additional 100 thousand cubic metres per day to be supplied between January 2026 and December 2027. The incremental volumes will be priced at 10.5% of average Brent crude oil prices in the preceding quarter.
NanoViricides (NYSE-A:NNVC) said on Wednesday it expects to begin a Phase II clinical trial of its antiviral candidate NV-387 for the treatment of mpox in the Democratic Republic of Congo (DRC) shortly.
The company said site preparations are underway, led by contract research organization Om Sai Clinical Research and local partners in the DRC.
Algernon Health (CSE:AGN, OTCQB:AGNPF, FRA:AGW0) said on Wednesday it plans to change its corporate name to Grey Matters Health Inc, reflecting a strategic shift toward brain health and the growing Alzheimer’s disease diagnostics market.
The company has reserved the new ticker symbol ‘GREY’ with the Canadian Securities Exchange and said updated symbols for its US and Frankfurt listings will be announced later.
374Water Inc (NASDAQ:SCWO, FRA:8LL) said it is focused on scaling its proprietary waste destruction technology and expanding commercial deployments in 2026, as the cleantech company builds on operational progress under new CEO Danny Bogar.
The company, which uses its AirSCWO technology to destroy organic waste and contaminants such as PFAS, is prioritizing disciplined execution, targeted capital allocation and measurable results.
The AIM-listed rare earths company upsized its placing after strong demand, though shares fell back on dilution concerns.
Shares in Mkango Resources Ltd (AIM:MKA, TSX-V:MKA, OTC:MKNGF), the rare earths developer, fell 13% to 33.6p on Wednesday despite the company completing a fundraise that was significantly oversubscribed and upsized from its original £10 million target to £12.5 million.
Arrow Exploration Corp (TSX-V:AXL, AIM:AXL, OTC:CSTPF) the Calgary-based oil producer focused on Colombia, has successfully drilled and brought into production a new well at its Mateguafa Attic field, adding to output at one of its most productive sites.
The Mateguafa 11 well, known as M-11, was spud (drilling began) on March 9 and reached its target depth within six days, completing ahead of schedule and under budget.
Manhattan Gold Corp Ltd (ASX:MHC, OTC:MHTZF, FRA:32U) has expanded its Hook Lake Project footprint by securing six new mineral claims covering an additional 81km² within the Kaminak Greenstone Belt, located about 30 kilometres west of its existing project area.
The move materially increases the company’s exposure to a highly prospective and underexplored gold belt, with the new ground hosting what has been described as the largest gold-in-till anomaly in the region. Importantly, this anomaly remains untested by drilling, highlighting the potential for new discoveries.
European Lithium Ltd (ASX:EUR, OTCQB:EULIF) extended its on-market share buy-back program, with the current buy-back closing on March 31, 2026 and a new six-month program set to run from April 15 to October 15, 2026.
The extension will operate within the Corporations Act’s 10/12 limit, allowing the company to repurchase up to 10% of its issued capital without shareholder approval. Shares acquired under the program will be cancelled, reducing total shares on issue. The company noted that the scale and timing of purchases will depend on prevailing market conditions, with Evolution Capital continuing as broker.
Lindian Resources Ltd (ASX:LIN, OTC:LINIF) has secured firm commitments to raise A$100 million through an institutional placement, strengthening its balance sheet and accelerating development across its flagship Kangankunde rare earths project and downstream processing strategy.
The placement, priced at A$0.75 per share, was strongly supported by domestic and offshore institutional investors and was oversubscribed, signalling continued investor appetite for near-term rare earths producers.
St George Mining Ltd (ASX:SGQ, FRA:S0G, OTC:SGQMF) is looking to reshape how niobium is produced at its flagship Araxá project in Brazil, signing a strategic alliance with US-based Boston Metal to trial a potentially game-changing processing technology.
The memorandum of understanding (MoU) will see the companies collaborate on testing Boston Metal’s molten oxide electrolysis (MOE) technology on niobium from Araxá, with the aim of improving production efficiency, lowering costs and reducing environmental impact.
American Rare Earths Ltd (ASX:ARR, OTCQX:ARRNF) is fast-tracking development at its flagship Halleck Creek project in Wyoming, advancing plans for a pilot plant program aimed at producing pre-production rare earth concentrate as it moves closer to potential commercialisation.
The company has engaged veteran metallurgical engineer Jaye T. Pickarts to lead the pilot plant process, bringing more than four decades of experience across mine development, mineral processing and rare earth demonstration facilities. His appointment is expected to support the integration and optimisation of the pilot circuit as ARR looks to de-risk the next stage of development.
Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) will present data from its lead cancer therapy candidate azer-cel in an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, marking a high-profile milestone for the company.
The clinical-stage immuno-oncology company said the azer-cel data had been selected for oral presentation at the conference, to be held from May 29 to June 2, 2026. ASCO is regarded as one of the world’s leading oncology meetings, with more than 8,500 abstracts reviewed this year by the Scientific Program Committee.